Keloids and hypertrophic scars occur anywhere from 30 to 90% of patients, and are
characterized by pathologically excessive dermal fibrosis and aberrant wound healing. Both …

Importance of chronic fibroproliferative diseases (FDs) including pulmonary fibrosis, chronic
kidney diseases, inflammatory bowel disease, and cardiovascular or liver fibrosis is rapidly …

Abstract Treatment of keloids (K) and hypertrophic scars (HTS) is challenging. A few case
reports reported good results in HTS treated by fractional CO 2 laser. The aim of the present …

Scarring, tightly associated with fibrosis, is a significant symptomatic clinical problem.
Interleukin 10 (IL-10) has been identified as a candidate scar-improving therapy based on …

Background The hypertrophic scar (HS) is a serious fibrotic skin condition and a major
clinical problem. Interleukin-10 (IL-10) has been identified as a prospective scar-improving …

Introduction: Keloids and hypertrophic scars are benign fibrous growths that occur after
trauma or wounding of the skin and present a major therapeutic problem. Objective: The …

Keloid disease (KD) is a common, benign, dermal fibroproliferative growth of unknown
aetiology. Lesions tend to grow over time; they often recur following therapy and do not …

Abstract Background and Aim Development of hepatic cirrhosis involves oxidative stress,
inflammation, hepatic stellate cells (HSC) s activation and fibrosis. On the other hand …

Purpose: Keloid is a poorly understood disease that is unique to humans. Hypertrophic
scars are similar to keloids and may transform into keloids over time. The standard …

Optimal management for keloid disease (KD) is ill defined, with surgical excision resulting in
recurrence rates over 50%. Photodynamic therapy (PDT) uses light to activate a …